Search results for: Adrian Towse
Filter search results
Assessing the Life-cycle Value of Second-generation Antipsychotics in Sweden and the UK
17 July 2019
… Citation Berdud, M., Wallin-Bernhardsson, N., Zamora, B., Lindgren, P., and Towse, A. (2019). Assessing the Life-cycle Value Added of Second-Generation Antipsychotics in Sweden and the UK: The Case…
Does Government Funding Increase Public Sector Development of New Medicines?
5 March 2021
…diseases in developed and developing countries. Health Economics, 28(1), pp.123–143. https://doi.org/10.1002/hec.3833. Danzon, P.M. and Towse, A., 2003. Differential Pricing for Pharmaceuticals: Reconciling Access, R&D and Patents. International Journal of Health…
How Does Pharmaceutical Spending Drive Innovation in Europe?
7 February 2022
…J., Sussex, J. and Towse, A., 2012. The R&D Cost of a New Medicine. [online] Office of Health Econom-ics. Available at: https://ideas.repec.org/b/ohe/monogr/000135.html [Accessed 27 Feb. 2021]. Towse, A. and Sharma,…
Invest to End TB. Save Lives. World TB Day 2022. Reflections on 60 years of OHE publications on TB
24 March 2022
…Tuberculosis. OHE Series on Health. Available from https://www.ohe.org/publications/tuberculosis. Kettler, H. and Towse, A. (2002) Public Private Partnerships for Research and Development: Medicines and Vaccines for Diseases of Poverty. OHE Monograph….
Payment Models for Multi-Indication Therapies
1 November 2021
…Cole, A., Towse, A., Lorgelly, P., and Sullivan, R. (2018) Economics of Innovative Payment Models Compared with Single Pricing of Pharmaceuticals. OHE Research Paper. Available from https://www.ohe.org/publications/economics-innovative-payment-models-compared-single-pricing-pharmaceuticals-0. Cole, A., Towse,…
Data Governance Arrangements for Real-world Evidence in Japan
12 September 2019
…position of commercial and non-commercial researchers in getting access to RWD to conduct research. Yasunaga, H., Yamana, H., Rodes Sanchez, M. and Towse, A., 2019. Data Governance Arrangements for Real-World…
HTA and Payment Mechanisms for New Drugs to Tackle AMR
23 September 2019
…and Towse, A., 2019. HTA and payment mechanisms for new drugs to tackle AMR. OHE Research Paper, London: Office of Health Economics. Available at: https://www.ohe.org/publications/hta-and-payment-mechanisms-new-drugs-tackle-amr Ferraro, J., Towse, A. and…
How do we Get and Pay for New Antibiotics? Proposed New Models for Value Assessment and Contracting for Payment.
26 March 2020
…to Australia to speak at Antibiotics 2020 was funded by MSD (Merck & Co.) Related Research: Ferraro, J., Towse, A. and Mestre-Ferrandiz, J., 2017. Incentives for New Drugs to Tackle…
The State of Play for Cost-effectiveness Thresholds
28 June 2022
…Sampson, C., Zamora, B., Watson, S., Cairns, J., Chalkidou, K., Cubi-Molla, P., Devlin, N., García-Lorenzo, B., Hughes, D.A., Leech, A.A. and Towse, A., 2022. Supply-Side Cost-Effectiveness Thresholds: Questions for Evidence-Based…